touchCARDIO touchCARDIO
COVID-19, Devices
Read Time: 2 mins

68/How often do we need to implant cardiac devices in COVID-19 patients – data from a single COVID-19-Hospital population

Copy Link
Published Online: Oct 3rd 2011 European Journal of Arrhythmia & Electrophysiology. 2021;7(Suppl. 1):abstr68
Authors: B Ignatiuk (Presenting Author) - Ospedali Riuniti Padova Sud, Monselice; L Leone - Ospedali Riuniti Padova Sud, Monselice; S Da Ros - Ospedali Riuniti Padova Sud, Monselice; D Montemurro - Ospedali Riuniti Padova Sud, Monselice; G Pasquetto - Ospedali Riuniti Padova Sud, Monselice
Quick Links:
Article
Article Information
Article:

Background: Despite the millions of people infected by SARSCoV-2 worldwide, there have only been few reports of cardiac device implantations in such subjects.

Purpose: We report a series of patients with SARS-CoV-2 who needed a permanent pacemaker.

Methods: Study of a single public hospital population in Northern Italy, entirely converted to a COVID-19-only facility during the SARS-CoV-2 pandemic. Data retrospectively collected from electronic medical history. We analysed the clinical profiles of patients implanted with pacemakers, the procedural safety, and the follow-up data.

Results: In total, 1,168 patients were hospitalized (during the spring outbreak from 21/02/2020 to 31/05/2020, and during the autumn phase, from mid-October until the end of 2020), mean age 72 years, 42% were females. All had a positive molecular nasopharyngeal swab for SARS-CoV-2 at admission. All but 5 were admitted because of COVID-19-related pneumonia requiring oxygen supplementation. The COVID-19 treatment was standardized according to the best knowledge of the time (including hydroxychloroquine and lopinavir during the spring outbreak and plasma/remdesivir during the autumn). In-hospital mortality was 22.3%. Four patients received a transvenous pacemaker (one during the spring wave and three in the autumn phase). The clinical information is summarized in Table 1. Only one subject had an overt SARS CoV-2 pneumonia at presentation and had an underlying aortic disease. A second pacemaker was implanted because of conduction disease in a patient with only incidental positivity at swab without any clinical manifestation of COVID-19. Two patients had moderate pneumonia on HRCT, but one was implanted late after pneumonia resolution, during readmission because of bradycardia. No peri- and post-procedural complications were observed. Personnel was negative on serial swabs. Two patients died during the follow-up (five months and two weeks after implantation, respectively).

Conclusions: In this large cohort of COVID-19 patients with symptomatic pneumonia, the pacemaker implantation rate was not higher than the implant rate in the general population. The bradyarrhythmias might not be necessarily related to the SARS-CoV-2 infection. The procedure may be performed safely both for the patient and for the personnel. The outcome is related to the severity of COVID-19 disease and individual patient factors.

Further Resources

Share this Article
Related Content In Devices
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72